![](/img/cover-not-exists.png)
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Platzbecker, Uwe, Middeke, Jan Moritz, Sockel, Katja, Herbst, Regina, Wolf, Dominik, Baldus, Claudia D, Oelschlägel, Uta, Mütherig, Anke, Fransecky, Lars, Noppeney, Richard, Bug, Gesine, Götze, KatharLanguage:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(18)30580-1
Date:
November, 2018
File:
PDF, 467 KB
english, 2018